

2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era
Tweetorial #3 References

Tweet 7

Giovannoni G, Lang S, Wolff R, et al. A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. *Neurol Ther.* 2020;9(2):359-374.

Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. *Am J Med.* 2020;133(12):1380-1390.e1382.

http://icerorg.wpengine.com/wp-content/uploads/2020/10/CTAF_MS_RAAG_030617.pdf

Lucchetta RC, Tonin FS, Borba HHL, et al. Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis. *CNS Drugs.* 2018;32(9):813-826.

Tweet 8

Aubagio. [full prescribing information]. 2012.

Avonex. [full prescribing information]. 2012

Bafiertam [full prescribing information]. 2020

Betaseron. [full prescribing information]. 1993

Copaxone [full prescribing information]. 2016

Gilenya [full prescribing information]. 2019

Mavenclad [full prescribing information]. 2019

Mayzent [full prescribing information]. 2021

Plegridy [full prescribing information]. 2020

Tecfidera [full prescribing information]. 2013

Vumerity [full prescribing information]. 2019

Zeposia [full prescribing information]. 2021

Tweet 9

Kesimpta [full prescribing information]. 2020

Lemtrada [full prescribing information]. 2021

Ocrevus [full prescribing information]. 2017

Tsybari [full prescribing information]. 2020

Tweet 12

Steinman et al. Efficacy and safety of ublituximab versus teriflunomide in relapsing multiple sclerosis: Results of the Phase 3 ULTIMATE I and II trials. 2021 AAN Annual Meeting, April 17-22. Poster 9056.

Tweet 13

Zappulla JP, Arock M, Mars LT, Liblau RS. Mast cells: new targets for multiple sclerosis therapy? *J Neuroimmunol.* 2002;131(1-2):5-20.

Tweet 15

Vermersch P, et al. Masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis: Results from phase 3 study AB07002. ACTRIMS/ECTRIMS MSVirtual 2020. *Multiple Sclerosis Journal* 2020;26(S3):9–42.

Tweet 17

Kolahdouzan M, Futhey NC, Kieran NW, Healy LM. Novel Molecular Leads for the Prevention of Damage and the Promotion of Repair in Neuroimmunological Disease. *Front Immunol.* 2019;10:1657.

Roach CA, Cross AH. Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis. *Front Neurol.* 2020;11:595547.

Tweet 18

Montalban X, Arnold DL, Weber MS, et al. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. *N Engl J Med.* 2019;380(25):2406-2417.

Glossary

5-HT, 5-hydroxytryptamine
AE, adverse effects
ALT, alanine aminotransferase
APC, antigen-presenting cell
ARR, Annualized Relapse Rate
BBB, blood-brain barrier
BBW, black box warning
BC, B cell
BID, bis in die (twice a day)
BTK, Bruton's tyrosine kinase
CD20, B-lymphocyte antigen
CD52, cluster of differentiation 52
CDI, clinical documentation improvement
CDW, confirmed disability worsening
CI, confidence interval
c-kit, tyrosine kinase receptor CD117
CNS, central nervous system
CSF, cerebrospinal fluid
DMF, Dimethyl fumarate
DMT, disease-modifying-therapy
DRF, Diroximel fumarate
EDSS, Expanded Disability Status Scale
GA, Glatiramer acetate
Gd, Gadolinium
GI, Gastrointestinal
H2H, head-to-head
HR, hazard ratio
HTN, hypertension
IFNbeta-1a, interferon beta-1a
IFNbeta-1b, interferon beta-1b
IV, intravenous
LRTI, ligament reconstruction and tendon interposition
MAS, masitinib
MMF, mycophenolate mofetil
MRI, magnetic resonance image
MS, multiple sclerosis
NEDA, No Evidence of Disease Activity
NP, nurse practitioner
Nrf2, nuclear factor erythroid 2
PA, Physician assistant
PBO, placebo
Peg INFbeta-1a, pegylated interferon beta-1a
Ph2, phase two

Ph3, phase three
Pharm, pharmacist
PML, progressive multifocal leukoencephalopathy
PPMS, Primary progressive MS
Pt, patient
QD, quaque die (once a day)
REBIF, recombinant beta interferon
RN, registered nurse
RTK, Receptor Tyrosine Kinase
S1PR, Sphingosine 1-Phosphate Receptor Modulators
SCF, stem cell factor
SPMS, secondary-progressive multiple sclerosis
T1, T1-weighted MRI sequence
T2, T2-weighted MRI sequence
TEAE, Treatment-Emergent Adverse Events
TER, teriflunomide
TNF- α , tumor necrosis factor alpha
Tx, treatment
URTI, upper respiratory tract infection
UTI, urinary tract infection
W, week
w/, with